FindAir, a Polish medtech company, has announced that it has received approval from the U.S. Food and Drug Administration for its FindAir ONE smart inhaler. The regulatory clearance marks a significant milestone for the company and represents an important step in bringing digital respiratory health management to patients in the United States.
The FindAir ONE device is designed to support the treatment and monitoring of respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD). Smart inhalers represent an emerging category of connected medical devices that combine traditional medication delivery with digital tracking and analytics capabilities to help patients manage their conditions more effectively.
Expanding into the U.S. market
The FDA approval enables FindAir to commercialize its smart inhaler solution in the United States, one of the world’s largest and most regulated medical device markets. This clearance follows the company’s earlier regulatory achievements in Europe, where it had already obtained the necessary certifications to market its technology.
Smart inhalers have gained increased attention within the healthcare sector due to their potential to improve medication adherence and provide healthcare providers with real-world data about patient usage patterns. These devices typically connect to mobile applications that can remind patients to take their medication and track inhaler usage over time.
Growing momentum in European healthtech
FindAir’s achievement reflects the growing strength of Poland’s medtech sector and the broader European healthtech ecosystem. European companies have become increasingly competitive in developing innovative solutions for chronic disease management, with many targeting international markets including the United States.
The company joins a wave of European medtech startups that have successfully navigated the complex regulatory landscape in the United States. This expansion demonstrates how Polish companies can scale beyond European borders and compete on a global stage in highly regulated industries such as healthcare.
The respiratory care market continues to represent a significant opportunity for digital health innovation. According to health organizations, millions of patients worldwide suffer from asthma and COPD, creating substantial demand for tools that can improve disease management and patient outcomes.
FindAir’s FDA approval underscores the maturation of the European medtech ecosystem and the capacity of companies from smaller EU markets to develop clinically validated solutions. As digital health technology becomes more integrated into standard respiratory care, companies offering connected devices and data analytics platforms are positioned to play an increasingly important role in patient management strategies across different healthcare systems.